Jo-Anne H. Young, Brent R. Logan, Juan Wu, John R. Wingard, Daniel J

Slides:

Advertisements

Similar presentations

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Advertisements

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation Karen Ballen, Kwang Woo Ahn, Min Chen, Hisham.

Gamma Delta T Cell Reconstitution Is Associated with Fewer Infections and Improved Event-Free Survival after Hematopoietic Stem Cell Transplantation for.

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome Joseph Delano F. Robles, Daniel.

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

How to Treat MDS without Stem Cell Transplantation

The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes Nancy H. Collins,

Health-related Quality of Life of Bone Marrow versus Peripheral Blood Stem Cell Donors: A Prespecified Subgroup Analysis from a Phase III RCT—BMTCTN Protocol.

Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Biology of Blood and Marrow Transplantation

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Incidence Rate of Fluoroquinolone-Resistant Gram-Negative Rod Bacteremia among Allogeneic Hematopoietic Cell Transplantation Patients during an Era of.

More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors Jo-Anne H. Young, MD, Brent R. Logan,

J. J. Nietfeld, Marcelo C. Pasquini, Brent R

Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Jill C. Beck, John E. Wagner, Todd E. DeFor, Claudio G

Claudio G. Brunstein, Bruce R. Blazar, Jeffrey S

HCMV Infection of Humanized Mice after Transplantation of G-CSF–Mobilized Peripheral Blood Stem Cells from HCMV-Seropositive Donors Morgan Hakki, Devorah.

Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance Allison M. Bock, Qing.

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Incidence of Post-Transplant Bacterial Foodborne Pathogens in Hematopoietic Stem Cell Transplant Patients Nicole Boyle, Sara Podczervinski, Kim Jordan,

Frederick R. Appelbaum, Claudio Anasetti, Joseph H

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or.

High-Resolution Match Rate of 7/8 and 9/10 or Better for the Be The Match Unrelated Donor Registry Kelly Buck, Kim Wadsworth, Michelle Setterholm, Martin.

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes over Time Celalettin.

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Blood and Marrow Transplant Handbook

T Cell–Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor.

Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation J.R. Molina,

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Mammen Chandy Biology of Blood and Marrow Transplantation

Treatment versus Transplant for Challenging Hematologic Disorders

Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow.

Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival Daniel Weisdorf,

Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell– Depleted Unrelated Bone Marrow: Analysis of Infectious Complications.

Mary Eapen Biology of Blood and Marrow Transplantation

In Memoriam: E. Donnall Thomas

Optimal Donor Selection: Beyond HLA

Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid.

Presentation transcript:

Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors Jo-Anne H. Young, Brent R. Logan, Juan Wu, John R. Wingard, Daniel J. Weisdorf, Cathryn Mudrick, Kristin Knust, Mary M. Horowitz, Dennis L. Confer, Erik R. Dubberke, Steven A. Pergam, Francisco M. Marty, Lynne M. Strasfeld, Janice (Wes) M. Brown, Amelia A. Langston, Mindy G. Schuster, Daniel R. Kaul, Stanley I. Martin, Claudio Anasetti Biology of Blood and Marrow Transplantation Volume 22, Issue 2, Pages 359-370 (February 2016) DOI: 10.1016/j.bbmt.2015.09.013 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Infection severity by treatment arm. (A) All infection events. (B) Maximum severity of infections (P = .60). Biology of Blood and Marrow Transplantation 2016 22, 359-370DOI: (10.1016/j.bbmt.2015.09.013) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Cumulative incidence of all infections. Biology of Blood and Marrow Transplantation 2016 22, 359-370DOI: (10.1016/j.bbmt.2015.09.013) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Cumulative incidence of specific infections. (A) Bacteria from all sites. (B) Bloodstream bacteria. (C) All viruses. (D) Cytomegalovirus. (E) All fungal/parasitic infections. (F) Aspergillus infections. Biology of Blood and Marrow Transplantation 2016 22, 359-370DOI: (10.1016/j.bbmt.2015.09.013) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Cumulative incidence of specific infections. (A) Bacteria from all sites. (B) Bloodstream bacteria. (C) All viruses. (D) Cytomegalovirus. (E) All fungal/parasitic infections. (F) Aspergillus infections. Biology of Blood and Marrow Transplantation 2016 22, 359-370DOI: (10.1016/j.bbmt.2015.09.013) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Infection density for each time period. (A) Total infection density. (B) Bacterial infection. (C) Viral infection. (D) Fungal infection. (E) Bloodstream bacterial infection. (F) Non–bloodstream bacterial infection. (G) Moderate infection. (H) Severe infection. (I) Life-threatening infection. Biology of Blood and Marrow Transplantation 2016 22, 359-370DOI: (10.1016/j.bbmt.2015.09.013) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Relationship of infection to engraftment. (A) Cumulative incidence of infections that occurred among engrafted patients. (B) Cumulative incidence of pre-engraftment infections. Biology of Blood and Marrow Transplantation 2016 22, 359-370DOI: (10.1016/j.bbmt.2015.09.013) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions